A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network

Bertha Hidalgo, Stella Aslibekyan, Howard W. Wiener, Marguerite R. Irvin, Robert J. Straka, Ingrid B. Borecki, Hemant K. Tiwari, Michael Y. Tsai, Paul N. Hopkins, Jose M. Ordovas, Donna K. Arnett

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Cost-effective identification of novel pharmacogenetic variants remains a pressing need in the field. Using data from the Genetics of Lipid Lowering Drugs and Diet Network, we identified genomic regions of relevance to fenofibrate response in a sample of 173 families. Our approach included a multipoint linkage scan, followed by selection of the families showing evidence of linkage. We identified a strong signal for changes in LDL-cholesterol (LDL-C) on chromosome 7 (peak logarithm of odds score=4.76) in the full sample (n=821). The signal for LDL-C response remained even after adjusting for baseline LDL-C. Restricting analyses only to the families contributing to the linkage signal for LDL-C (N=19), we observed a peak logarithm of odds score of 5.17 for chromosome 7. Two genes under this peak (ABCB4 and CD36) were of biological interest. These results suggest that linked family analyses might be a useful approach to gene discovery in the presence of a complex (e.g. multigenic) phenotype.

Original languageEnglish
Pages (from-to)511-514
Number of pages4
JournalPharmacogenetics and Genomics
Volume25
Issue number10
DOIs
StatePublished - Sep 23 2015

Bibliographical note

Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

  • family study
  • fenofibrate
  • lipids

ASJC Scopus subject areas

  • Genetics(clinical)
  • General Pharmacology, Toxicology and Pharmaceutics
  • Genetics
  • Molecular Medicine
  • Molecular Biology

Fingerprint

Dive into the research topics of 'A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network'. Together they form a unique fingerprint.

Cite this